JP2009201510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009201510A5 JP2009201510A5 JP2009120409A JP2009120409A JP2009201510A5 JP 2009201510 A5 JP2009201510 A5 JP 2009201510A5 JP 2009120409 A JP2009120409 A JP 2009120409A JP 2009120409 A JP2009120409 A JP 2009120409A JP 2009201510 A5 JP2009201510 A5 JP 2009201510A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- residues
- protein
- clyta
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 229920000272 Oligonucleotide Polymers 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000282326 Felis catus Species 0.000 description 4
- 230000000692 anti-sense Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 3
- 108060007869 BAH1 Proteins 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- 102100019937 DHRS2 Human genes 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100003017 MAGEA3 Human genes 0.000 description 1
- 101710027664 MAGEA3 Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
Description
従ってコアのサインの共通パターンは次の通りであり、ここでxはいずれかのアミノ酸を指し、小文字の残基は保存され(保存性変異を許容する)、大文字の残基は完全に保存される。
コア配列のサイン(配列番号:16)
LixvL(2x)I(3x)g(2x)apEExiWexl(2x)m(3-4x)Gxe(3-4x)gxp(2x)llt(3x)VqexYLxYxqVPxsxP(2x)yeFLWGprA(2x)Et(3x)kv
保存性置換は公知であり、一般に配列アラインメントプログラムにおいてデフォルトスコアリングマトリックスとして設定される。これらのプログラムには、PAM250 (Dayhoft M.O.ら、(1978), “A model of evolutionary changes in proteins¨, In“Atlas of Protein sequence and structure¨ 5 (3) M.O. Dayhoft (ed.), 345-352), National Biomedical Research Foundation, Washington、及びBlosum 62 (Steven Henikoft and Jorja G. Henikoft (1992),“Amino acid substitution matricies from protein blocks¨), Proc.Natl.Acad.Sci. USA 89 (Biochemistry): 10915-10919 がある。
コア配列のサイン(配列番号:16)
LixvL(2x)I(3x)g(2x)apEExiWexl(2x)m(3-4x)Gxe(3-4x)gxp(2x)llt(3x)VqexYLxYxqVPxsxP(2x)yeFLWGprA(2x)Et(3x)kv
保存性置換は公知であり、一般に配列アラインメントプログラムにおいてデフォルトスコアリングマトリックスとして設定される。これらのプログラムには、PAM250 (Dayhoft M.O.ら、(1978), “A model of evolutionary changes in proteins¨, In“Atlas of Protein sequence and structure¨ 5 (3) M.O. Dayhoft (ed.), 345-352), National Biomedical Research Foundation, Washington、及びBlosum 62 (Steven Henikoft and Jorja G. Henikoft (1992),“Amino acid substitution matricies from protein blocks¨), Proc.Natl.Acad.Sci. USA 89 (Biochemistry): 10915-10919 がある。
融合タンパク質を発現するプラスミドは、18アミノ酸シグナル配列及び処理されたプロテインDの最初の109残基、2つの無関係なアミノ酸(Met及びAsp)、MAGE−3のアミノ酸残基3〜314、後に7つのHis残基に露出されるヒンジ領域をして機能する2つのGly残基を含む前駆タンパク質を発現するようデザインした(配列番号2;配列番号1によりコードされる)。
a)オリゴヌクレオチドセンス:5′gc gcc atg gat ctg gaa cag cgt agt cag cac tgc aag cct(配列番号:11)及びオリゴヌクレオチドアンチセンス:5′gcg tct aga tta atg gtg atg gtg atg gtg atg acc gcc ctc ttc ccc ctc tct caa(配列番号:12)を用いてプラスミドcDNA MAGE3内に供される配列のPCR増幅;この増幅は、N末端に以下の改変を導く:最初の5つのコドンの、大腸菌コドン使用への変化、位置1におけるProコドンのAspコドンによる置換、5′末端でのNcoI部位の設置及び2つのGlyコドン及び7つのHisコドン、その後のXbaI部位の、C末端での最後の付加。
融合パートナーとしての処理したプロテインDの最初の109残基の包含は、T細胞エピトープを有するワクチン抗原を供する。LPD成分の他に、タンパク質は、2つの無関係なアミノ酸(Met及びAsp)、Mage−3のアミノ酸残基3〜314、次の7つのヒスチジン残基を露出するためのヒンジ領域として機能する2つのGly残基を含む。
図13に概説するクローニングストラテジーは以下のステップを含む:
a)オリゴヌクレオチドセンス:5′gc gcc atg gat ctg gaa cag cgt agt cag cac tgc aag cct(配列番号:11)、及びオリゴヌクレオチドアンチセンス:5′gcg tct aga tta atg gtg atg gtg atg gtg atg acc gcc ctc ttc ccc ctc tct caa(配列番号:12)を用いて、プラスミドcDNA MAGE−3内に供される配列のPCR増幅。
a)オリゴヌクレオチドセンス:5′gc gcc atg gat ctg gaa cag cgt agt cag cac tgc aag cct(配列番号:11)、及びオリゴヌクレオチドアンチセンス:5′gcg tct aga tta atg gtg atg gtg atg gtg atg acc gcc ctc ttc ccc ctc tct caa(配列番号:12)を用いて、プラスミドcDNA MAGE−3内に供される配列のPCR増幅。
CLYTA−Mage−1−Hisタンパク質の発現のためのクローニングストラテジー(図16の概説を参照のこと)は以下のステップを含む:
2.CLYTA−Mage−1−Hisコーディング配列モジュールの調製:
a)最初のステップは、CLYTA配列をNdeI−AflIII 制限部位に隣接させることを予定したPCR増幅であった。そのPCR増幅は、プラスミドPCUZ1テンプレート及びプライマーとしてオリゴヌクレオチドセンス:5′tta aac cac acc tta agg agg ata taa cat atg aaa ggg gga att gta cat tca gac(配列番号:13)、及びオリゴヌクレオチドアンチセンス:5′GCC AGA CAT GTC CAA TTC TGG CCT GTC TGC CAG(配列番号:14)を用いて行った。これは、378ヌクレオチド長のCLYTA配列の増幅を導く。
2.CLYTA−Mage−1−Hisコーディング配列モジュールの調製:
a)最初のステップは、CLYTA配列をNdeI−AflIII 制限部位に隣接させることを予定したPCR増幅であった。そのPCR増幅は、プラスミドPCUZ1テンプレート及びプライマーとしてオリゴヌクレオチドセンス:5′tta aac cac acc tta agg agg ata taa cat atg aaa ggg gga att gta cat tca gac(配列番号:13)、及びオリゴヌクレオチドアンチセンス:5′GCC AGA CAT GTC CAA TTC TGG CCT GTC TGC CAG(配列番号:14)を用いて行った。これは、378ヌクレオチド長のCLYTA配列の増幅を導く。
CLYTA−MAGE−3−Hisタンパク質の発現のためのクローニングストラテジー(図19の概説を参照のこと)は以下のステップを含む。
1.CLYTA−MAGE−3−Hisコーディング配列モジュールの調製:
1.1.最初のステップはAflII及びAflIII 制限部位にCLYTAを隣接させることを予定したPCR増幅であった。PCR増幅は、テンプレートとしてプラスミドPCUZ1及びプライマーとしてオリゴヌクレオチドセンス:5′tta aac cac acc tta agg agg ata taa cat atg aaa ggg gga att gta cat tca gac(配列番号:13)、及びオリゴヌクレオチドアンチセンス:5′ccc aca tgt cca gac tgc tgg cca att ctg gcc tgt ctg cca gtg(配列番号:15)を用いて行った。これは、427ヌクレオチド長CLYTA配列の増幅を導く。先に増幅したフラグメントをInvitrogenのTAクローニングベクターにクローン化して、中間体ベクターpRIT14661を得た。
1.CLYTA−MAGE−3−Hisコーディング配列モジュールの調製:
1.1.最初のステップはAflII及びAflIII 制限部位にCLYTAを隣接させることを予定したPCR増幅であった。PCR増幅は、テンプレートとしてプラスミドPCUZ1及びプライマーとしてオリゴヌクレオチドセンス:5′tta aac cac acc tta agg agg ata taa cat atg aaa ggg gga att gta cat tca gac(配列番号:13)、及びオリゴヌクレオチドアンチセンス:5′ccc aca tgt cca gac tgc tgg cca att ctg gcc tgt ctg cca gtg(配列番号:15)を用いて行った。これは、427ヌクレオチド長CLYTA配列の増幅を導く。先に増幅したフラグメントをInvitrogenのTAクローニングベクターにクローン化して、中間体ベクターpRIT14661を得た。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9802543.0A GB9802543D0 (en) | 1998-02-05 | 1998-02-05 | Vaccine |
GBGB9802650.3A GB9802650D0 (en) | 1998-02-06 | 1998-02-06 | Vaccine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000530602A Division JP4768121B2 (ja) | 1998-02-05 | 1999-02-02 | Mageファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009201510A JP2009201510A (ja) | 2009-09-10 |
JP2009201510A5 true JP2009201510A5 (ja) | 2010-04-02 |
Family
ID=26313069
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000530602A Expired - Fee Related JP4768121B2 (ja) | 1998-02-05 | 1999-02-02 | Mageファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用 |
JP2009120409A Pending JP2009201510A (ja) | 1998-02-05 | 2009-05-18 | Mageファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000530602A Expired - Fee Related JP4768121B2 (ja) | 1998-02-05 | 1999-02-02 | Mageファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用 |
Country Status (26)
Country | Link |
---|---|
US (3) | US8097257B2 (ja) |
EP (4) | EP1659178B1 (ja) |
JP (2) | JP4768121B2 (ja) |
KR (2) | KR100824105B1 (ja) |
CN (1) | CN1227360C (ja) |
AR (1) | AR018064A1 (ja) |
AT (4) | ATE462788T1 (ja) |
AU (1) | AU737337B2 (ja) |
BR (1) | BR9907691B1 (ja) |
CA (2) | CA2319309C (ja) |
CY (4) | CY1105685T1 (ja) |
CZ (2) | CZ298364B6 (ja) |
DE (3) | DE69942214D1 (ja) |
DK (4) | DK1584685T3 (ja) |
ES (2) | ES2255248T3 (ja) |
HK (4) | HK1033838A1 (ja) |
HU (1) | HU228467B1 (ja) |
IL (4) | IL137442A0 (ja) |
NO (2) | NO328507B1 (ja) |
NZ (1) | NZ506086A (ja) |
PT (4) | PT1584685E (ja) |
SA (1) | SA99200126B1 (ja) |
SI (4) | SI1659179T1 (ja) |
TR (1) | TR200002284T2 (ja) |
TW (1) | TWI238853B (ja) |
WO (1) | WO1999040188A2 (ja) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ298364B6 (cs) | 1998-02-05 | 2007-09-05 | Smithkline Beecham Biologicals S. A. | Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci |
ES2222728T3 (es) | 1998-10-05 | 2005-02-01 | Pharmexa A/S | Procedimiento de vacunacion terapeutica. |
EP1502602A3 (en) * | 1998-10-05 | 2006-05-17 | Pharmexa A/S | Methods for therapeutic vaccination |
GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
CA2400842C (en) | 2000-02-23 | 2013-01-15 | Smithkline Beecham Biologicals S.A. | Novel compounds |
EP1385541B1 (en) * | 2000-04-13 | 2008-06-18 | Corixa Corporation | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 |
AU5810201A (en) * | 2000-05-10 | 2001-11-20 | Aventis Pasteur | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
AUPQ761200A0 (en) | 2000-05-19 | 2000-06-15 | Hunter Immunology Limited | Compositions and methods for treatment of mucosal infections |
DE60140868D1 (de) * | 2000-06-05 | 2010-02-04 | Brigham & Womens Hospital | Für ein homologes des humanen, für mehrfachresistenz verantwortlichen, p-glykoproteins auf chromosom 7p15-21 kodierendes gen sowie verwendungen dafür |
DK2133100T3 (da) | 2000-06-20 | 2012-01-23 | Corixa Corp | MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf |
PT1889630E (pt) | 2000-10-18 | 2012-02-29 | Glaxosmithkline Biolog Sa | Vacinas compreendendo o antigénio mage ligado a um fragmento da proteína d |
NZ525320A (en) * | 2000-10-18 | 2004-10-29 | Glaxosmithkline Biolog S | Combinations of immunostimulatory oligonucleotides (CpG), saponin and optionally lipopolysaccharides as potent vaccine adjuvants |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
WO2003050268A2 (en) | 2001-12-12 | 2003-06-19 | Aventis Pasteur Limited | Enhancement of the immune response using cd36-binding domain |
ES2359473T3 (es) | 2003-07-21 | 2011-05-23 | Transgene S.A. | Citoquinas multifuncionales. |
EP1660526A1 (en) * | 2003-08-29 | 2006-05-31 | The Nottingham Trent University | Gastric and prostate cancer associated antigens |
AU2004281634B2 (en) * | 2003-09-03 | 2011-01-27 | Dendritherapeutics, Inc. | Multiplex vaccines |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
GB0409940D0 (en) * | 2004-05-04 | 2004-06-09 | Glaxosmithkline Biolog Sa | Vaccine |
CN101184504A (zh) | 2005-03-31 | 2008-05-21 | 葛兰素史密丝克莱恩生物有限公司 | 针对衣原体感染的疫苗 |
CN101273055B (zh) | 2005-04-29 | 2016-03-16 | 葛兰素史密丝克莱恩生物有限公司 | 用于预防或治疗结核分枝杆菌感染的新方法 |
CA2608579C (en) * | 2005-05-26 | 2019-09-10 | Cytos Biotechnology Ag | Scalable fermentation process |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
EP2305827A1 (en) * | 2005-11-14 | 2011-04-06 | Université Laval | Cancer antigen MAGE-A9 and uses thereof |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
JP5170976B2 (ja) | 2006-04-11 | 2013-03-27 | 株式会社イミュノフロンティア | タンパク質複合体およびその製造方法 |
EP2390356A1 (en) | 2006-06-02 | 2011-11-30 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the FASLG gene |
GB0612342D0 (en) * | 2006-06-21 | 2006-08-02 | Glaxosmithkline Biolog Sa | Method |
PL2486938T3 (pl) | 2006-09-26 | 2018-08-31 | Infectious Disease Research Institute | Kompozycja szczepionki zawierająca syntetyczny adiuwant |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
GB0700284D0 (en) * | 2007-01-08 | 2007-02-14 | Glaxosmithkline Biolog Sa | Combination therapy |
AR064862A1 (es) * | 2007-01-15 | 2009-04-29 | Glaxosmithkline Biolog Sa | Proteinas de fusion que comprenden un antigeno de rechazo tumoral prame (dage) |
RU2010114058A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение пептида в качестве терапевтического средства |
WO2009046827A2 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
NZ596545A (en) * | 2007-09-17 | 2013-05-31 | Glaxosmithkline Biolog Sa | Improved detection of mage-a expression |
DK2200642T3 (da) * | 2007-10-19 | 2012-07-16 | Novartis Ag | Meningococvaccinepræparater |
EA021100B1 (ru) | 2009-03-17 | 2015-04-30 | МДхХЭЛС СА | Усовершенствованное определение экспрессии генов |
EA020617B1 (ru) | 2009-05-27 | 2014-12-30 | Глаксосмитклайн Байолоджикалс С.А. | Конструкции casb7439 |
ES2606563T3 (es) | 2009-06-05 | 2017-03-24 | Infectious Disease Research Institute | Adyuvantes lipídicos de glucopiranosilo sintéticos y composiciones de vacuna que contienen los mismos |
GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
JP6010463B2 (ja) | 2010-01-27 | 2016-10-19 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 改変された結核抗原 |
GB201022007D0 (en) | 2010-12-24 | 2011-02-02 | Imp Innovations Ltd | DNA-sensor |
EP2675473A1 (en) | 2011-02-15 | 2013-12-25 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
BRPI1100857A2 (pt) * | 2011-03-18 | 2013-05-21 | Alexandre Eduardo Nowill | agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real |
EP2694099B1 (en) | 2011-04-08 | 2019-10-16 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
CN102251034B (zh) * | 2011-07-05 | 2012-11-21 | 北京大学人民医院 | 基于mage-c2/ct10基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒 |
KR102004559B1 (ko) | 2011-08-30 | 2019-07-26 | 아스텍스 파마수티컬스, 인크. | 데시타빈 유도체 제제 |
GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
RU2014122867A (ru) * | 2011-12-22 | 2016-02-20 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Способ лечения рака иммунотерапевтическим средством, специфичным в отношении MAGEA3, совместно с ингибитором BRAF и/или ингибитором MEK |
LT2811981T (lt) | 2012-02-07 | 2019-06-10 | Infectious Disease Research Institute | Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai |
PL2850431T3 (pl) | 2012-05-16 | 2018-09-28 | Immune Design Corp. | Szczepionki przeciwko HSV-2 |
EP2912069B1 (en) | 2012-10-23 | 2019-07-31 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
CN110448566A (zh) | 2013-03-01 | 2019-11-15 | 阿斯泰克斯制药公司 | 药物组合 |
SG11201508092YA (en) | 2013-04-18 | 2015-10-29 | Immune Design Corp | Gla monotherapy for use in cancer treatment |
US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
WO2015092710A1 (en) | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Contralateral co-administration of vaccines |
EA201691348A1 (ru) | 2013-12-31 | 2016-11-30 | Инфекшес Дизиз Рисерч Инститьют | Однофлаконные вакцинные составы |
SG11201606625RA (en) | 2014-02-14 | 2016-09-29 | Immune Design Corp | Immunotherapy of cancer through combination of local and systemic immune stimulation |
CA2955015A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
JP6768722B2 (ja) | 2015-07-02 | 2020-10-14 | 大塚製薬株式会社 | 凍結乾燥医薬組成物 |
CN105181966B (zh) * | 2015-09-02 | 2017-08-11 | 南通大学附属医院 | 一种mage‑a9的用途 |
KR102566134B1 (ko) | 2015-12-07 | 2023-08-10 | 삼성전자주식회사 | 반도체 소자의 3d 프로파일링 시스템 및 이의 동작 방법 |
WO2017176076A1 (en) | 2016-04-06 | 2017-10-12 | Ewha University - Industry Collaboration Foundation | A peptide with ability to penetrate cell membrane |
CA3020542A1 (en) | 2016-04-11 | 2017-10-19 | Board Of Regents, The University Of Texas System | Methods and compositions for detecting single t cell receptor affinity and sequence |
CA3023672A1 (en) | 2016-05-16 | 2017-11-23 | Infectious Disease Research Institute | Pegylated liposomes and methods of use |
WO2017200852A1 (en) | 2016-05-16 | 2017-11-23 | Infectious Disease Research Institute | Formulation containing tlr agonist and methods of use |
MX2018014399A (es) | 2016-06-01 | 2019-06-06 | Infectious Disease Res Inst | Particulas de nanoalumbre que contienen un agente de dimensionamiento. |
CA3067224A1 (en) | 2017-06-15 | 2018-12-20 | Infectious Disease Research Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
BR112020002280A2 (pt) | 2017-08-03 | 2020-07-28 | Otsuka Pharmaceutical Co., Ltd. | composto farmacológico e métodos purificação do mesmo |
JP7339942B2 (ja) | 2017-09-08 | 2023-09-06 | アクセス ツー アドバンスト ヘルス インスティチュート | サポニンを含むリポソーム製剤および使用方法 |
US20220033848A1 (en) | 2018-11-19 | 2022-02-03 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
WO2020113029A2 (en) | 2018-11-28 | 2020-06-04 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
BR112021010248A2 (pt) | 2018-11-29 | 2021-08-17 | Board Of Regents, The University Of Texas System | métodos para expansão ex vivo de células naturais killer e uso dos mesmos |
CA3141577A1 (en) | 2019-05-25 | 2020-12-03 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
EP4107173A1 (en) | 2020-02-17 | 2022-12-28 | Board of Regents, The University of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
AU2021337493A1 (en) | 2020-09-04 | 2023-05-18 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
WO2022051024A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Genetically-adjuvanted rna vaccines |
WO2022104109A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
US20220162288A1 (en) | 2020-11-25 | 2022-05-26 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
US20240050561A1 (en) | 2020-12-23 | 2024-02-15 | Access To Advanced Health Institute | Solanesol vaccine adjuvants and methods of preparing same |
EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
WO2023089556A1 (en) | 2021-11-22 | 2023-05-25 | Pfizer Inc. | Reducing risk of antigen mimicry in immunogenic medicaments |
WO2023211972A1 (en) | 2022-04-28 | 2023-11-02 | Medical University Of South Carolina | Chimeric antigen receptor modified regulatory t cells for treating cancer |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4384995A (en) | 1980-01-16 | 1983-05-24 | The Ohio State University | Antigenic modification of polypeptides |
US4526716A (en) | 1981-11-20 | 1985-07-02 | The Ohio State University | Antigenic modification of polypeptides |
US4302386A (en) | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
AR241713A1 (es) | 1984-08-30 | 1992-11-30 | Smithkline Beckman Corp | Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe. |
ZA896627B (en) * | 1988-08-31 | 1991-03-27 | Smithkline Beecham Corp | Vaccinal polypeptides |
GB8824496D0 (en) | 1988-10-19 | 1988-11-23 | Beecham Group Plc | Process |
US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
CA2022752C (en) | 1989-08-11 | 1998-07-07 | Naomi Kitamura | Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor |
GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
DK0547064T3 (da) | 1990-07-23 | 1995-03-20 | Zymogenetics Inc | Proteaseresistent PDGF og anvendelsesfremgangsmåde |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US5925729A (en) | 1991-05-23 | 1999-07-20 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
US5541104A (en) | 1991-05-23 | 1996-07-30 | Ludwig Institute For Cancer Research | Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 |
EP1025853A3 (en) | 1991-11-14 | 2000-11-08 | Brigham And Women's Hospital | Pharmaceutical composition containing S-nitroso-heme proteins and use thereof |
GB9213559D0 (en) * | 1992-06-25 | 1992-08-12 | Smithkline Beecham Biolog | Vaccines |
KR100278157B1 (ko) | 1992-06-25 | 2001-01-15 | 장 스테판느 | 보조약을 함유하는 백신 조성물 |
EP0658113B1 (en) | 1992-08-31 | 2004-10-20 | Ludwig Institute For Cancer Research | Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof |
AU702517B2 (en) * | 1993-08-06 | 1999-02-25 | Epimmune, Inc. | Cloning and characterization of the complete MAGE-1 gene |
GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
NZ282536A (en) | 1994-03-01 | 1998-07-28 | Ludwig Inst Cancer Res | Nucleic acid molecule useful as a primer in determining expression of a mage tumour rejections antigen precursor |
US5879687A (en) * | 1994-04-22 | 1999-03-09 | Corixa Corporation | Methods for enhancement of protective immune responses |
EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
JPH10511639A (ja) * | 1994-09-30 | 1998-11-10 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | 腫瘍拒絶抗原前駆体または腫瘍拒絶抗原を含有する組成物ならびにアジュバント及び/又は成長因子 |
US5612030A (en) * | 1995-01-17 | 1997-03-18 | University Of Kentucky Research Foundation | Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
US6017705A (en) | 1995-03-14 | 2000-01-25 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
AU6283496A (en) | 1995-06-29 | 1997-01-30 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule which encodes murine tumor rejection antigen precursor smage-3 |
AU7440196A (en) | 1995-10-12 | 1997-04-30 | Chiron Corporation | Baboon mage-3 homologs, dna encoding the homologs, and a process for their use |
US6265215B1 (en) | 1996-09-13 | 2001-07-24 | Ludwig Institute For Cancer Research | Isolated peptides which complex with HLA-Cw16 and uses thereof |
US5908778A (en) | 1996-10-03 | 1999-06-01 | Ludwig Institute For Cancer Research | Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof |
US6030780A (en) | 1996-10-15 | 2000-02-29 | The Rockefeller University | Purified Stat proteins and methods of purifying thereof |
WO1998020165A2 (en) | 1996-11-06 | 1998-05-14 | Whitehead Institute For Biomedical Research | Biallelic markers |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
US6340461B1 (en) | 1996-12-17 | 2002-01-22 | David Stephen Terman | Superantigen based methods and compositions for treatment of diseases |
US6287569B1 (en) | 1997-04-10 | 2001-09-11 | The Regents Of The University Of California | Vaccines with enhanced intracellular processing |
US6680191B1 (en) | 1997-04-25 | 2004-01-20 | Ludwig Institute For Cancer | Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof |
US20020176865A1 (en) | 1997-04-25 | 2002-11-28 | Sophie Lucas | Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B families and uses thereof |
US6027924A (en) | 1997-04-25 | 2000-02-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof |
US6043084A (en) | 1997-10-10 | 2000-03-28 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer |
US6291430B1 (en) | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
US5965535A (en) | 1997-09-12 | 1999-10-12 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
US6716809B1 (en) | 1997-09-12 | 2004-04-06 | Ludwig Institute For Cancer Research | Mage-A3 peptides presented by HLA class molecules |
CZ298364B6 (cs) | 1998-02-05 | 2007-09-05 | Smithkline Beecham Biologicals S. A. | Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci |
WO1999053095A2 (en) | 1998-04-09 | 1999-10-21 | Whitehead Institute For Biomedical Research | Biallelic markers |
US6686147B1 (en) | 1998-07-15 | 2004-02-03 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
-
1999
- 1999-02-02 CZ CZ20002869A patent/CZ298364B6/cs not_active IP Right Cessation
- 1999-02-02 KR KR1020067008476A patent/KR100824105B1/ko not_active IP Right Cessation
- 1999-02-02 BR BRPI9907691-8A patent/BR9907691B1/pt not_active IP Right Cessation
- 1999-02-02 DE DE69942214T patent/DE69942214D1/de not_active Expired - Lifetime
- 1999-02-02 AT AT06075362T patent/ATE462788T1/de active
- 1999-02-02 HU HU0102639A patent/HU228467B1/hu not_active IP Right Cessation
- 1999-02-02 EP EP06075362A patent/EP1659178B1/en not_active Expired - Lifetime
- 1999-02-02 DE DE69929310T patent/DE69929310T2/de not_active Expired - Lifetime
- 1999-02-02 IL IL13744299A patent/IL137442A0/xx active IP Right Grant
- 1999-02-02 AT AT06075363T patent/ATE513042T1/de active
- 1999-02-02 NZ NZ506086A patent/NZ506086A/xx not_active IP Right Cessation
- 1999-02-02 EP EP06075363A patent/EP1659179B1/en not_active Expired - Lifetime
- 1999-02-02 PT PT05076599T patent/PT1584685E/pt unknown
- 1999-02-02 AT AT05076599T patent/ATE505542T1/de active
- 1999-02-02 CA CA2319309A patent/CA2319309C/en not_active Expired - Fee Related
- 1999-02-02 JP JP2000530602A patent/JP4768121B2/ja not_active Expired - Fee Related
- 1999-02-02 ES ES99907476T patent/ES2255248T3/es not_active Expired - Lifetime
- 1999-02-02 DK DK05076599.9T patent/DK1584685T3/da active
- 1999-02-02 EP EP99907476A patent/EP1053325B1/en not_active Expired - Lifetime
- 1999-02-02 EP EP05076599A patent/EP1584685B1/en not_active Expired - Lifetime
- 1999-02-02 PT PT06075362T patent/PT1659178E/pt unknown
- 1999-02-02 SI SI9931061T patent/SI1659179T1/sl unknown
- 1999-02-02 PT PT06075363T patent/PT1659179E/pt unknown
- 1999-02-02 CA CA2584482A patent/CA2584482C/en not_active Expired - Fee Related
- 1999-02-02 DK DK06075362.1T patent/DK1659178T3/da active
- 1999-02-02 DE DE69943359T patent/DE69943359D1/de not_active Expired - Lifetime
- 1999-02-02 DK DK06075363.9T patent/DK1659179T3/da active
- 1999-02-02 CZ CZ20060442A patent/CZ298347B6/cs not_active IP Right Cessation
- 1999-02-02 SI SI9931044T patent/SI1659178T1/sl unknown
- 1999-02-02 SI SI9930879T patent/SI1053325T1/sl unknown
- 1999-02-02 AT AT99907476T patent/ATE315088T1/de active
- 1999-02-02 AU AU27220/99A patent/AU737337B2/en not_active Ceased
- 1999-02-02 SI SI9931053T patent/SI1584685T1/sl unknown
- 1999-02-02 WO PCT/EP1999/000660 patent/WO1999040188A2/en active Application Filing
- 1999-02-02 PT PT99907476T patent/PT1053325E/pt unknown
- 1999-02-02 CN CNB998046043A patent/CN1227360C/zh not_active Expired - Fee Related
- 1999-02-02 TR TR2000/02284T patent/TR200002284T2/xx unknown
- 1999-02-02 ES ES06075362T patent/ES2342416T3/es not_active Expired - Lifetime
- 1999-02-02 DK DK99907476T patent/DK1053325T3/da active
- 1999-02-02 KR KR1020007008550A patent/KR100633212B1/ko not_active IP Right Cessation
- 1999-02-04 AR ARP990100475A patent/AR018064A1/es active IP Right Grant
- 1999-02-12 TW TW088102224A patent/TWI238853B/zh not_active IP Right Cessation
- 1999-05-16 SA SA99200126A patent/SA99200126B1/ar unknown
-
2000
- 2000-07-21 IL IL137442A patent/IL137442A/en not_active IP Right Cessation
- 2000-08-04 NO NO20003958A patent/NO328507B1/no not_active IP Right Cessation
-
2001
- 2001-05-11 HK HK01103307A patent/HK1033838A1/xx not_active IP Right Cessation
- 2001-05-11 HK HK06101448.0A patent/HK1083026A1/xx not_active IP Right Cessation
- 2001-05-11 HK HK06111055.3A patent/HK1093522A1/xx not_active IP Right Cessation
- 2001-05-11 HK HK06111054.4A patent/HK1093521A1/xx not_active IP Right Cessation
-
2006
- 2006-03-07 CY CY20061100310T patent/CY1105685T1/el unknown
- 2006-11-02 IL IL179010A patent/IL179010A0/en unknown
-
2008
- 2008-01-17 IL IL188875A patent/IL188875A/en not_active IP Right Cessation
-
2009
- 2009-04-27 NO NO20091665A patent/NO331719B1/no not_active IP Right Cessation
- 2009-05-18 JP JP2009120409A patent/JP2009201510A/ja active Pending
- 2009-12-17 US US12/640,306 patent/US8097257B2/en not_active Expired - Fee Related
-
2010
- 2010-03-12 US US12/722,691 patent/US8044183B2/en not_active Expired - Fee Related
- 2010-06-10 CY CY20101100509T patent/CY1110180T1/el unknown
-
2011
- 2011-07-08 CY CY20111100663T patent/CY1111672T1/el unknown
- 2011-09-14 CY CY20111100885T patent/CY1111831T1/el unknown
- 2011-12-13 US US13/324,509 patent/US8597656B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009201510A5 (ja) | ||
US7517854B2 (en) | Melanocortin receptor agonists | |
JP2008529558A5 (ja) | ||
JP2013502226A5 (ja) | ||
ES2295054T3 (es) | Peptido c para la produccion mejorada de insulina y analogos de insulina. | |
EP2377938A1 (en) | Capping-prone RNA polymerase enzymes and their applications | |
JP2014527818A (ja) | Wnt組成物およびそのような組成物の治療的使用 | |
JP2011514144A5 (ja) | ||
EP0877804A1 (en) | Inhibitors of cell-cycle progression, and uses related thereto | |
JP2006149395A5 (ja) | ||
KR102483242B1 (ko) | Mg53 돌연변이체, 및 그의 제조 방법 및 그의 용도 | |
EP3291843A1 (en) | Modified ube3a gene for a gene therapy approach for angelman syndrome | |
JP2013515081A5 (ja) | ||
JP2020510426A5 (ja) | ||
JP2010534060A5 (ja) | ||
Bossier et al. | Structure and expression of a yeast gene encoding the small heat-shock protein Hsp26 | |
JP2009507474A5 (ja) | ||
SI23902A (sl) | Samosestavljivi polipeptidni poliedri | |
WO1993003152A1 (en) | Igf-ii analogues | |
JP2005508158A5 (ja) | ||
Iacobazzi et al. | Organization and sequence of the human gene for the mitochondrial citrate transport protein | |
JP6480872B2 (ja) | インスリン分泌性ポリペプチド | |
WO2004015083A2 (en) | Compositions and uses of motor protein-binding moieties | |
CA2086509C (fr) | Nouveau variant gp160 non-clivable, soluble, de forme hybride | |
WO2022219333A1 (en) | Signal peptides |